Ken Griffin Aurinia Pharmaceuticals Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 141,500 shares of AUPH stock, worth $1.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

141,500

Previous 110,800 27.71%

Holding current value

$1.27 Million

Previous $632,000 64.08%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$5.32 - $7.33 $2.08 Million - $2.87 Million	-390,920 Reduced 41.69%	546,872 $4.01 Million
Q2 2024 Aug 14, 2024	BUY	$4.81 - $5.78 $3.22 Million - $3.87 Million	669,389 Added 249.4%	937,792 $5.35 Million
Q1 2024 May 15, 2024	SELL	$4.93 - $9.31 $1.53 Million - $2.89 Million	-310,262 Reduced 53.62%	268,403 $1.34 Million
Q4 2023 Feb 14, 2024	SELL	$7.13 - $9.49 $422,374 - $562,178	-59,239 Reduced 9.29%	578,665 $5.2 Million
Q3 2023 Nov 14, 2023	BUY	$7.77 - $12.27 $2.14 Million - $3.39 Million	275,906 Added 76.22%	637,904 $4.96 Million
Q2 2023 Aug 14, 2023	SELL	$8.96 - $11.69 $18.7 Million - $24.4 Million	-2,085,275 Reduced 85.21%	361,998 $3.5 Million
Q1 2023 May 15, 2023	SELL	$5.94 - $11.27 $7.9 Million - $15 Million	-1,329,989 Reduced 35.21%	2,447,273 $26.8 Million
Q4 2022 Feb 14, 2023	BUY	$4.11 - $8.14 $4.22 Million - $8.36 Million	1,027,146 Added 37.35%	3,777,262 $16.3 Million
Q3 2022 Nov 14, 2022	BUY	$6.66 - $12.39 $12.5 Million - $23.3 Million	1,880,872 Added 216.38%	2,750,116 $20.7 Million
Q2 2022 Aug 15, 2022	SELL	$8.95 - $12.8 $2.51 Million - $3.58 Million	-279,902 Reduced 24.36%	869,244 $8.74 Million
Q1 2022 May 16, 2022	BUY	$10.05 - $22.48 $4.34 Million - $9.71 Million	431,853 Added 60.21%	1,149,146 $14.2 Million
Q4 2021 Feb 14, 2022	BUY	$17.78 - $33.08 $1.72 Million - $3.21 Million	96,960 Added 15.63%	717,293 $16.4 Million
Q3 2021 Nov 15, 2021	SELL	$10.93 - $23.55 $928,634 - $2 Million	-84,962 Reduced 12.05%	620,333 $13.7 Million
Q2 2021 Aug 16, 2021	SELL	$10.0 - $14.52 $7.28 Million - $10.6 Million	-727,898 Reduced 50.79%	705,295 $9.14 Million
Q1 2021 May 17, 2021	SELL	$12.3 - $18.73 $502,516 - $765,214	-40,855 Reduced 2.77%	1,433,193 $18.6 Million
Q4 2020 Feb 16, 2021	SELL	$12.94 - $16.05 $25.9 Million - $32.2 Million	-2,004,162 Reduced 57.62%	1,474,048 $20.4 Million
Q3 2020 Nov 16, 2020	BUY	$13.19 - $16.66 $34 Million - $43 Million	2,578,478 Added 286.58%	3,478,210 $51.2 Million
Q2 2020 Aug 14, 2020	SELL	$14.12 - $18.33 $5.06 Million - $6.57 Million	-358,654 Reduced 28.5%	899,732 $14.6 Million
Q1 2020 May 15, 2020	BUY	$11.34 - $21.46 $3.64 Million - $6.89 Million	320,895 Added 34.23%	1,258,386 $18.3 Million
Q4 2019 Feb 14, 2020	BUY	$3.88 - $21.42 $3.42 Million - $18.9 Million	882,480 Added 1604.19%	937,491 $19 Million
Q3 2019 Nov 14, 2019	SELL	$5.34 - $6.59 $245,832 - $303,377	-46,036 Reduced 45.56%	55,011 $293,000
Q2 2019 Aug 14, 2019	SELL	$6.05 - $6.75 $214,617 - $239,449	-35,474 Reduced 25.98%	101,047 $665,000
Q1 2019 May 15, 2019	BUY	$6.06 - $7.64 $123,399 - $155,573	20,363 Added 17.53%	136,521 $0
Q4 2018 Feb 14, 2019	SELL	$5.08 - $6.83 $101,747 - $136,798	-20,029 Reduced 14.71%	116,158 $792,000
Q3 2018 Nov 13, 2018	BUY	$5.27 - $6.64 $449,346 - $566,159	85,265 Added 167.44%	136,187 $0
Q1 2018 May 11, 2018	SELL	$4.85 - $5.99 $370,379 - $457,438	-76,367 Reduced 59.99%	50,922 $264,000
Q4 2017 Feb 09, 2018	BUY	$4.53 - $7.09 $522,712 - $818,108	115,389 Added 969.66%	127,289 $577,000
Q3 2017 Nov 09, 2017	BUY	$5.71 - $6.9 $67,949 - $82,110	11,900	11,900 $75,000

Others Institutions Holding AUPH

# of Institutions

207

Shares Held

58.6M

Call Options Held

1.14M

Put Options Held

1.51M

View Full List

About Aurinia Pharmaceuticals Inc.

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.27B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

More about AUPH

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account